The Most Favored Nation Model fails to ensure that vulnerable Medicare beneficiaries have access to safe, unrestricted care when they need it.
(Last Updated December 16, 2020)
The Administration explicitly states that a portion of the model’s savings ‘is attributable to beneficiaries not accessing their drugs through the Medicare benefit, along with the associated lost utilization.’ To learn more about what this interim final rule language entails and what this will mean for infusion centers come January 1, 2021.
Read NICA's Joint Press Release (December 4, 2020)
“Statement on Litigation Challenging Legality of the Administration’s Most Favored Nation Rule”
Read NICA's Response to the Trump Administration's Decision to Move Forward
November 23, 2020
Read the Centers for Medicare & Medicaid (CMS) Press Release
November 20, 2020
Read the Full Rule
Public comments on the rule can be submitted through the link below and must be received no later than 60 days after publication of the IFC in the Federal Register.
Medicare Part B and International Drug Pricing
This is an ASPE report on Medicare Part B drug spending and international price comparisons.